Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2019.1880
Abstract: Importance The antithrombotic treatment of patients with atrial fibrillation (AF) and coronary artery disease, in particular with acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), poses a significant treatment dilemma in clinical practice. Objective… read more here.
Keywords: inhibitor; analysis; p2y12 inhibitor; safety ... See more keywords
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.3203
Abstract: Importance Although P2Y12 inhibitor monotherapy after a minimum period of dual antiplatelet therapy (DAPT) is a well-known way to reduce the risk of bleeding after percutaneous coronary intervention (PCI), data comparing long-term clinical outcomes between… read more here.
Keywords: p2y12 inhibitor; long term; inhibitor monotherapy; trial ... See more keywords
P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.0877
Abstract: Key Points Question Is P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy (DAPT; a P2Y12 inhibitor plus aspirin) noninferior to 12 months of DAPT in terms of net adverse clinical events (a composite… read more here.
Keywords: inhibitor monotherapy; dual antiplatelet; p2y12 inhibitor;
P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.52070
Abstract: Hematoma expansion (HE) predicts disability and death after acute intracerebral hemorrhage (ICH). Aspirin and anticoagulants have been associated with HE. We tested the hypothesis that P2Y12 inhibitors predict subsequent HE in patients. We explored laboratory… read more here.
Keywords: intracerebral hemorrhage; p2y12 inhibitor; hematoma expansion;
Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI—the POPular Risk Score study
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-019-02696-z
Abstract: PurposeThe POPular Risk Score was developed for the selective intensification of P2Y12 inhibitor treatment with prasugrel instead of clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI) with stent implantation. This score is based on… read more here.
Keywords: risk; risk score; popular risk; p2y12 inhibitor ... See more keywords
P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00947-x
Abstract: Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) reduces the incidence of thrombotic events but increases the risk of bleeding, which is associated with a substantial and durable risk of death and could offset… read more here.
Keywords: monotherapy short; p2y12 inhibitor; term; inhibitor monotherapy ... See more keywords
CYP2C19 genotype-directed P2Y12 inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention
Sign Up to like & getrecommendations! Published in 2021 at "Indian Heart Journal"
DOI: 10.1016/j.ihj.2021.03.004
Abstract: Objective To study the use of CYP2C19 genotyping to guide P2Y12 inhibitor selection to maximize efficacy, and attenuate risk in appropriate patients who underwent PCI for CAD. Methods We performed a retrospective analysis of 868… read more here.
Keywords: cyp2c19; risk; p2y12 inhibitor; cyp2c19 genotype ... See more keywords
P2Y12 INHIBITOR MONOTHERAPY AFTER A SHORT DUAL ANTIPLATELET THERAPY VS. 12-MONTH DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)30700-2
Abstract: Dual Antiplatelet Therapy (DAPT) after PCI reduces the incidence of thrombotic events but increases the risk of bleeding, which is associated with a substantial and durable risk of death and could offset the benefits of… read more here.
Keywords: p2y12 inhibitor; dual antiplatelet; inhibitor monotherapy; antiplatelet therapy ... See more keywords
Reversible P2Y12 inhibitor versus irreversible P2Y12 inhibitor in ACS patients undergoing PCI (the acute coronary syndrome israeli survey (ACSIS)
Sign Up to like & getrecommendations! Published in 2021 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehab724.1414
Abstract: Based on data from randomized controlled trials, both American and European guidelines recommend treating acute coronary syndrome (ACS) patients with second generation P2Y12 inhibitors.1,2 Direct head-to-head comparison of these agents was scarce until the recent… read more here.
Keywords: inhibitor; p2y12 inhibitor; acs patients; irreversible thienopyridine ... See more keywords
Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Sign Up to like & getrecommendations! Published in 2025 at "European heart journal"
DOI: 10.1093/eurheartj/ehaf718
Abstract: Antiplatelet therapy is the cornerstone of treatment in patients with established atherosclerotic disease. The use of a single antiplatelet agent is commonly recommended for the long-term management of these patients. Although aspirin has represented the… read more here.
Keywords: disease; aspirin p2y12; aspirin; inhibitor monotherapy ... See more keywords
Maintained P2Y12 inhibitor monotherapy after shorter-duration of dual antiplatelet therapy in patients undergoing coronary drug-eluting stents implantation: An updated meta-analysis of randomized trials.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacy and therapeutics"
DOI: 10.1111/jcpt.13626
Abstract: WHAT IS KNOWN AND OBJECTIVE It is well known that high in-stent thrombotic risk due to the superimposition of a platelet-rich thrombus was considered as the main origin of major adverse cardiac events after stent… read more here.
Keywords: inhibitor monotherapy; antiplatelet; p2y12 inhibitor; antiplatelet therapy ... See more keywords